



Clinical trial results:

A randomized, subject and investigator blinded, placebo-controlled, multi-center study in parallel groups to assess the efficacy and safety of CJM112 in patients with moderate to severe inflammatory acne

Summary

EudraCT number	2016-002492-95
Trial protocol	DE NL
Global end of trial date	01 August 2018

Results information

Result version number	v2 (current)
This version publication date	03 July 2022
First version publication date	22 August 2019
Version creation reason	<ul style="list-style-type: none">• New data added to full data setActual doses added to treatment arms

Trial information

Trial identification

Sponsor protocol code	CCJM112X2203
-----------------------	--------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02998671
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Novartis Pharma AG
Sponsor organisation address	CH-4002, Basel, Switzerland,
Public contact	Clinical Disclosure Office, Novartis Pharma AG, 41 613241111, novartis.email@novartis.com
Scientific contact	Clinical Disclosure Office, Novartis Pharma AG, 41 613241111, novartis.email@novartis.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	01 August 2018
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	01 August 2018
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

To assess the efficacy of CJM112 versus placebo on facial inflammatory lesion counts in patients with moderate to severe inflammatory acne.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	22 December 2016
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Germany: 18
Country: Number of subjects enrolled	Netherlands: 13
Country: Number of subjects enrolled	United States: 21
Worldwide total number of subjects	52
EEA total number of subjects	31

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	52
From 65 to 84 years	0

85 years and over	0
-------------------	---

Subject disposition

Recruitment

Recruitment details:

A total of approximately 75 subjects were planned to be enrolled in the study. The study was terminated early due to futility after a total of 52 subjects were enrolled and randomized.

Pre-assignment

Screening details:

For period 1 (12 weeks) subjects were randomized to one of the 3 treatment groups CJM112 high dose, CJM112 low dose or placebo.

For Period 2 (12 weeks) subjects treated with Placebo in Period 1 were rerandomized to CJM112 high dose or CJM112 low dose. All other subjects remained on the same dose.

Period 1

Period 1 title	Period 1
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	P1: CJM112 high dose (300mg) / P2: CJM112 high dose (300mg)

Arm description:

CJM112 high dose (300mg) in treatment period 1 (Day 1 - 85) ; CJM112 high dose (300mg) in extension period 2 (Day 86 - 169)

Arm type	Experimental
Investigational medicinal product name	CJM112
Investigational medicinal product code	CJM112
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Injection once a month in period 1

Arm title	P1: CJM112 low dose (75mg) / P2: CJM112 low dose (75mg)
------------------	---

Arm description:

CJM112 low dose (75mg) in treatment period 1 (Day 1 - 85) ; CJM112 low dose (75mg) in extension period 2 (Day 86 - 169)

Arm type	Experimental
Investigational medicinal product name	CJM112
Investigational medicinal product code	CJM112
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Injection once a month in period 1

Arm title	P1: Placebo / P2 CJM112 low dose or high dose
------------------	---

Arm description:

Placebo in treatment period 1 (Day 1 - 85) ; CJM112 low dose (75mg) or CJM112 high dose (300mg) in extension period 2 (Day 86 - 169)

Arm type	Placebo
----------	---------

Investigational medicinal product name	Placebo
Investigational medicinal product code	Placebo
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use
Dosage and administration details:	
Injection once a month in period 1	

Number of subjects in period 1	P1: CJM112 high dose (300mg) / P2: CJM112 high dose (300mg)	P1: CJM112 low dose (75mg) / P2: CJM112 low dose (75mg)	P1: Placebo / P2: CJM112 low dose or high dose
Started	21	13	18
Completed	17	10	14
Not completed	4	3	4
Consent withdrawn by subject	1	2	2
Study Terminated By Sponsor	2	1	1
Adverse event, non-fatal	-	-	1
Pregnancy	1	-	-

Period 2

Period 2 title	Period 2
Is this the baseline period?	No
Allocation method	Non-randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	P1: CJM112 high dose (300mg)/ P2: CJM112 high dose (300mg)

Arm description:

CJM112 high dose (300mg) in treatment period 1 (Day 1 - 85) ; CJM112 high dose (300mg) in extension period 2 (Day 86 - 169)

Arm type	Experimental
Investigational medicinal product name	CJM112
Investigational medicinal product code	CJM112
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Injection once a month in period 2

Arm title	P1: CJM112 low dose (75mg) / P2: CJM112 low dose (75mg)
------------------	---

Arm description:

CJM112 low dose (75mg) in treatment period 1 (Day 1 - 85) ; CJM112 low dose (75mg) in extension

period 2 (Day 86 - 169)

Arm type	Experimental
Investigational medicinal product name	CJM112
Investigational medicinal product code	CJM112
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use
Dosage and administration details:	
Injection once a month in period 2	
Arm title	P1: Placebo / P2 CJM112 low dose or high dose

Arm description:

Placebo in treatment period 1 (Day 1 - 85) ; CJM112 low dose (75mg) or CJM112 high dose (300mg) in extension period 2 (Day 86 - 169)

Arm type	Experimental
Investigational medicinal product name	CJM112
Investigational medicinal product code	CJM112
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Injection once a month in period 2

Number of subjects in period 2	P1: CJM112 high dose (300mg)/ P2: CJM112 high dose (300mg)	P1: CJM112 low dose (75mg) / P2: CJM112 low dose (75mg)	P1: Placebo / P2 CJM112 low dose or high dose
Started	17	10	14
Completed	14	3	9
Not completed	3	7	5
Consent withdrawn by subject	-	1	-
Study Terminated By Sponsor	3	5	4
Adverse event, non-fatal	-	1	-
Lost to follow-up	-	-	1

Baseline characteristics

Reporting groups

Reporting group title	P1: CJM112 high dose (300mg) / P2: CJM112 high dose (300mg)
Reporting group description: CJM112 high dose (300mg) in treatment period 1 (Day 1 - 85) ; CJM112 high dose (300mg) in extension period 2 (Day 86 - 169)	
Reporting group title	P1: CJM112 low dose (75mg) / P2: CJM112 low dose (75mg)
Reporting group description: CJM112 low dose (75mg) in treatment period 1 (Day 1 - 85) ; CJM112 low dose (75mg) in extension period 2 (Day 86 - 169)	
Reporting group title	P1: Placebo / P2 CJM112 low dose or high dose
Reporting group description: Placebo in treatment period 1 (Day 1 - 85) ; CJM112 low dose (75mg) or CJM112 high dose (300mg) in extension period 2 (Day 86 - 169)	

Reporting group values	P1: CJM112 high dose (300mg) / P2: CJM112 high dose (300mg)	P1: CJM112 low dose (75mg) / P2: CJM112 low dose (75mg)	P1: Placebo / P2 CJM112 low dose or high dose
Number of subjects	21	13	18
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	21	13	18
From 65-84 years	0	0	0
85 years and over	0	0	0
Age Continuous Units: years			
arithmetic mean	23.8	25.5	23.9
standard deviation	± 4.19	± 5.99	± 4.07
Sex: Female, Male Units: Subjects			
Female	13	8	13
Male	8	5	5
Race/Ethnicity, Customized Units: Subjects			
White	18	10	17
Other	3	3	1

Reporting group values	Total		
Number of subjects	52		

Age categorical			
Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	52		
From 65-84 years	0		
85 years and over	0		
Age Continuous			
Units: years			
arithmetic mean			
standard deviation	-		
Sex: Female, Male			
Units: Subjects			
Female	34		
Male	18		
Race/Ethnicity, Customized			
Units: Subjects			
White	45		
Other	7		

End points

End points reporting groups

Reporting group title	P1: CJM112 high dose (300mg) / P2: CJM112 high dose (300mg)
-----------------------	---

Reporting group description:

CJM112 high dose (300mg) in treatment period 1 (Day 1 - 85) ; CJM112 high dose (300mg) in extension period 2 (Day 86 - 169)

Reporting group title	P1: CJM112 low dose (75mg) / P2: CJM112 low dose (75mg)
-----------------------	---

Reporting group description:

CJM112 low dose (75mg) in treatment period 1 (Day 1 - 85) ; CJM112 low dose (75mg) in extension period 2 (Day 86 - 169)

Reporting group title	P1: Placebo / P2 CJM112 low dose or high dose
-----------------------	---

Reporting group description:

Placebo in treatment period 1 (Day 1 - 85) ; CJM112 low dose (75mg) or CJM112 high dose (300mg) in extension period 2 (Day 86 - 169)

Reporting group title	P1: CJM112 high dose (300mg)/ P2: CJM112 high dose (300mg)
-----------------------	--

Reporting group description:

CJM112 high dose (300mg) in treatment period 1 (Day 1 - 85) ; CJM112 high dose (300mg) in extension period 2 (Day 86 - 169)

Reporting group title	P1: CJM112 low dose (75mg) / P2: CJM112 low dose (75mg)
-----------------------	---

Reporting group description:

CJM112 low dose (75mg) in treatment period 1 (Day 1 - 85) ; CJM112 low dose (75mg) in extension period 2 (Day 86 - 169)

Reporting group title	P1: Placebo / P2 CJM112 low dose or high dose
-----------------------	---

Reporting group description:

Placebo in treatment period 1 (Day 1 - 85) ; CJM112 low dose (75mg) or CJM112 high dose (300mg) in extension period 2 (Day 86 - 169)

Subject analysis set title	P1: Placebo / P2: CJM112 high dose
----------------------------	------------------------------------

Subject analysis set type	Sub-group analysis
---------------------------	--------------------

Subject analysis set description:

Placebo in treatment period 1; CJM112 high dose in extension period 2

Subject analysis set title	P1: Placebo / P2: CJM112 low dose
----------------------------	-----------------------------------

Subject analysis set type	Sub-group analysis
---------------------------	--------------------

Subject analysis set description:

Placebo in treatment period 1; CJM112 low dose in extension period 2

Primary: Total inflammatory facial lesion count at day 85

End point title	Total inflammatory facial lesion count at day 85
-----------------	--

End point description:

Total inflammatory facial lesion count was the total count of papules, pustules and nodules assessed at day 85

End point type	Primary
----------------	---------

End point timeframe:

Day 85

End point values	P1: CJM112 high dose (300mg) / P2: CJM112 high dose (300mg)	P1: CJM112 low dose (75mg) / P2: CJM112 low dose (75mg)	P1: Placebo / P2 CJM112 low dose or high dose	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	17	10	15	
Units: Lesions				
geometric mean (confidence interval 90%)	21.9 (16.58 to 29.14)	20.3 (13.76 to 29.66)	18.5 (13.51 to 25.13)	

Statistical analyses

Statistical analysis title	Total inflammatory facial lesion count
Comparison groups	P1: CJM112 high dose (300mg) / P2: CJM112 high dose (300mg) v P1: Placebo / P2 CJM112 low dose or high dose
Number of subjects included in analysis	32
Analysis specification	Pre-specified
Analysis type	
Method	Bayesian model for repeated measurements
Parameter estimate	Ratio of geometric means
Point estimate	1.18
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.79
upper limit	1.81

Statistical analysis title	Total inflammatory facial lesion count
Comparison groups	P1: CJM112 low dose (75mg) / P2: CJM112 low dose (75mg) v P1: Placebo / P2 CJM112 low dose or high dose
Number of subjects included in analysis	25
Analysis specification	Pre-specified
Analysis type	
Method	Bayesian model for repeated measurements
Parameter estimate	Ratio of geometric means
Point estimate	1.1
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.66
upper limit	1.8

Secondary: Number and severity of adverse events in Period 1

End point title	Number and severity of adverse events in Period 1
-----------------	---

End point description:	
Frequency and severity of adverse events in Period 1	
End point type	Secondary
End point timeframe:	
Day 1 to Day 85	

End point values	P1: CJM112 high dose (300mg) / P2: CJM112 high dose (300mg)	P1: CJM112 low dose (75mg) / P2: CJM112 low dose (75mg)	P1: Placebo / P2 CJM112 low dose or high dose	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	21	13	18	
Units: Adverse Events				
Number of AEs of mild intensity	27	25	20	
Number of AEs of moderate intensity	5	7	9	
Number of AEs of severe intensity	0	1	0	

Statistical analyses

No statistical analyses for this end point

Secondary: Number and severity of adverse events in Period 2

End point title	Number and severity of adverse events in Period 2 ^[1]
End point description:	
Frequency and severity of adverse events in Period 2	
End point type	Secondary
End point timeframe:	
Day 86 to Day 260	

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: no statistical analysis performed

End point values	P1: CJM112 high dose (300mg) / P2: CJM112 high dose (300mg)	P1: CJM112 low dose (75mg) / P2: CJM112 low dose (75mg)	P1: Placebo / P2: CJM112 high dose	P1: Placebo / P2: CJM112 low dose
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	17	10	6	8
Units: Adverse Events				
Number of AEs of mild intensity	21	20	6	13
Number of AEs of moderate intensity	6	1	3	1
Number of AEs of severe intensity	1	1	0	0

Statistical analyses

No statistical analyses for this end point

Secondary: Pharmacokinetics (PK): Serum trough concentrations of CJM112 in Period 1

End point title	Pharmacokinetics (PK): Serum trough concentrations of CJM112 in Period 1 ^[2]
End point description:	Pharmacokinetics (PK): Serum trough concentrations of CJM112
End point type	Secondary
End point timeframe:	Day 1, Day 29, Day 57 and Day 85

Notes:

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: no statistical analysis performed

End point values	P1: CJM112 high dose (300mg) / P2: CJM112 high dose (300mg)	P1: CJM112 low dose (75mg) / P2: CJM112 low dose (75mg)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	21	12		
Units: ng/mL				
arithmetic mean (standard deviation)				
Period 1 Day 1 (Pre Dose)	152 (± 663)	0 (± 0)		
Period 1 Day 29 (Pre Dose)	8670 (± 3370)	802 (± 961)		
Period 1 Day 57 (Pre Dose)	11500 (± 5020)	1550 (± 1130)		
Period 1 Day 85 (Pre Dose)	17000 (± 8080)	2040 (± 1570)		

Statistical analyses

No statistical analyses for this end point

Secondary: Pharmacokinetics (PK): Serum trough concentrations of CJM112 in Period 2

End point title	Pharmacokinetics (PK): Serum trough concentrations of CJM112 in Period 2 ^[3]
End point description:	Pharmacokinetics (PK): Serum trough concentrations of CJM112
End point type	Secondary
End point timeframe:	Day 85, Day 113, Day 141 and Day 169

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: no statistical analysis performed

End point values	P1: CJM112 high dose (300mg) / P2: CJM112 high dose (300mg)	P1: CJM112 low dose (75mg) / P2: CJM112 low dose (75mg)	P1: Placebo / P2: CJM112 high dose	P1: Placebo / P2: CJM112 low dose
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	21	12	6	8
Units: ng/mL				
arithmetic mean (standard deviation)				
Period 2 Day 85 (Pre Dose)	17000 (± 8080)	2040 (± 1570)	713 (± 1750)	0 (± 0)
Period 2 Day 113 (Pre Dose)	15900 (± 8140)	1890 (± 634)	8260 (± 5120)	1430 (± 1190)
Period 2 Day 141 (Pre Dose)	18700 (± 9450)	3140 (± 2180)	15700 (± 10700)	3700 (± 1250)
Period 2 Day 169 (Pre Dose)	19400 (± 9650)	3890 (± 1890)	16600 (± 6610)	2890 (± 672)

Statistical analyses

No statistical analyses for this end point

Secondary: Number of patients with clinically significant abnormal hematology laboratory parameters

End point title	Number of patients with clinically significant abnormal hematology laboratory parameters
End point description: Abnormalities were considered clinically significant by the Investigator if they could impact the study conduct or safety of the subjects.	
End point type	Secondary
End point timeframe: 38 Weeks	

End point values	P1: CJM112 high dose (300mg) / P2: CJM112 high dose (300mg)	P1: CJM112 low dose (75mg) / P2: CJM112 low dose (75mg)	P1: Placebo / P2: CJM112 low dose or high dose	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	21	13	18	
Units: Participants	0	0	0	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of patients with clinically significant abnormal clinical chemistry laboratory parameters parameters

End point title	Number of patients with clinically significant abnormal clinical chemistry laboratory parameters
End point description: Abnormalities were considered clinically significant by the Investigator if they could impact the study conduct or safety of the subjects. Clinically significant abnormalities are also reported as Adverse Events.	
End point type	Secondary
End point timeframe: 38 Weeks	

End point values	P1: CJM112 high dose (300mg) / P2: CJM112 high dose (300mg)	P1: CJM112 low dose (75mg) / P2: CJM112 low dose (75mg)	P1: Placebo / P2 CJM112 low dose or high dose	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	21	13	18	
Units: Participants				
Period 1	3	0	0	
Period 2	0	3	2	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of patients with clinically significant abnormal urinalysis laboratory parameters

End point title	Number of patients with clinically significant abnormal urinalysis laboratory parameters
End point description: Abnormalities were considered clinically significant by the Investigator if they could impact the study conduct or safety of the subjects.	
End point type	Secondary
End point timeframe: 38 Weeks	

End point values	P1: CJM112 high dose (300mg) / P2: CJM112 high dose (300mg)	P1: CJM112 low dose (75mg) / P2: CJM112 low dose (75mg)	P1: Placebo / P2 CJM112 low dose or high dose	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	21	13	18	
Units: Participants	0	0	0	

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

38 weeks

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	21.0
--------------------	------

Reporting groups

Reporting group title	Period 1 CJM112 low dose
-----------------------	--------------------------

Reporting group description:

Period 1 CJM112 low dose

Reporting group title	Period 1 CJM112 high dose
-----------------------	---------------------------

Reporting group description:

Period 1 CJM112 high dose

Reporting group title	Period 1 Pooled CJM112
-----------------------	------------------------

Reporting group description:

Period 1 Pooled CJM112

Reporting group title	Period 1 Placebo
-----------------------	------------------

Reporting group description:

Period 1 Placebo

Reporting group title	Period 2 CJM112 high dose/CJM112 high dose
-----------------------	--

Reporting group description:

Period 2 CJM112 high dose/CJM112 high dose

Reporting group title	Period 2 Placebo/ CJM112 high dose
-----------------------	------------------------------------

Reporting group description:

Period 2 Placebo/ CJM112 high dose

Reporting group title	Period 2 CJM112 low dose/CJM112 low dose
-----------------------	--

Reporting group description:

Period 2 CJM112 low dose/CJM112 low dose

Reporting group title	Period 2 Placebo/ CJM112 low dose
-----------------------	-----------------------------------

Reporting group description:

Period 2 Placebo/ CJM112 low dose

Reporting group title	Period 2 Pooled CJM112 high dose
-----------------------	----------------------------------

Reporting group description:

Period 2 Pooled CJM112 high dose

Reporting group title	Period 2 Pooled CJM112 low dose
-----------------------	---------------------------------

Reporting group description:

Period 2 Pooled CJM112 low dose

Serious adverse events	Period 1 CJM112 low dose	Period 1 CJM112 high dose	Period 1 Pooled CJM112
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 13 (0.00%)	0 / 21 (0.00%)	0 / 34 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0

Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 21 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Period 1 Placebo	Period 2 CJM112 high dose/CJM112 high dose	Period 2 Placebo/CJM112 high dose
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	0 / 6 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Period 2 CJM112 low dose/CJM112 low dose	Period 2 Placebo/CJM112 low dose	Period 2 Pooled CJM112 high dose
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 10 (0.00%)	0 / 8 (0.00%)	1 / 23 (4.35%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 8 (0.00%)	1 / 23 (4.35%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Period 2 Pooled CJM112 low dose		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 18 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Hepatobiliary disorders			
Cholelithiasis			

subjects affected / exposed	0 / 18 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 3 %

Non-serious adverse events	Period 1 CJM112 low dose	Period 1 CJM112 high dose	Period 1 Pooled CJM112
Total subjects affected by non-serious adverse events			
subjects affected / exposed	11 / 13 (84.62%)	16 / 21 (76.19%)	27 / 34 (79.41%)
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 13 (0.00%)	0 / 21 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	1 / 13 (7.69%)	0 / 21 (0.00%)	1 / 34 (2.94%)
occurrences (all)	2	0	2
Influenza like illness			
subjects affected / exposed	0 / 13 (0.00%)	1 / 21 (4.76%)	1 / 34 (2.94%)
occurrences (all)	0	1	1
Injection site bruising			
subjects affected / exposed	0 / 13 (0.00%)	1 / 21 (4.76%)	1 / 34 (2.94%)
occurrences (all)	0	2	2
Injection site reaction			
subjects affected / exposed	1 / 13 (7.69%)	0 / 21 (0.00%)	1 / 34 (2.94%)
occurrences (all)	3	0	3
Non-cardiac chest pain			
subjects affected / exposed	0 / 13 (0.00%)	0 / 21 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Sensation of foreign body			
subjects affected / exposed	0 / 13 (0.00%)	0 / 21 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 13 (0.00%)	0 / 21 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0

Seasonal allergy subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 21 (0.00%) 0	0 / 34 (0.00%) 0
Reproductive system and breast disorders Dysmenorrhoea subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 21 (0.00%) 0	1 / 34 (2.94%) 1
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all) Dyspnoea subjects affected / exposed occurrences (all) Nasal congestion subjects affected / exposed occurrences (all) Oropharyngeal pain subjects affected / exposed occurrences (all) Rhinorrhoea subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1 0 / 13 (0.00%) 0 0 / 13 (0.00%) 0 1 / 13 (7.69%) 1 0 / 13 (0.00%) 0	0 / 21 (0.00%) 0 0 / 21 (0.00%) 0 0 / 21 (0.00%) 0 1 / 21 (4.76%) 1 1 / 21 (4.76%) 1	1 / 34 (2.94%) 1 0 / 34 (0.00%) 0 0 / 34 (0.00%) 0 2 / 34 (5.88%) 2 1 / 34 (2.94%) 1
Psychiatric disorders Depression subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 21 (0.00%) 0	0 / 34 (0.00%) 0
Investigations Alanine aminotransferase increased subjects affected / exposed occurrences (all) Aspartate aminotransferase increased subjects affected / exposed occurrences (all) Blood creatine phosphokinase increased	0 / 13 (0.00%) 0 0 / 13 (0.00%) 0 0 / 13 (0.00%) 0	1 / 21 (4.76%) 1 0 / 21 (0.00%) 0 0 / 21 (0.00%) 0	1 / 34 (2.94%) 1 0 / 34 (0.00%) 0 0 / 34 (0.00%) 0

subjects affected / exposed	0 / 13 (0.00%)	1 / 21 (4.76%)	1 / 34 (2.94%)
occurrences (all)	0	1	1
Blood creatinine increased			
subjects affected / exposed	0 / 13 (0.00%)	0 / 21 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Blood triglycerides increased			
subjects affected / exposed	0 / 13 (0.00%)	1 / 21 (4.76%)	1 / 34 (2.94%)
occurrences (all)	0	2	2
Glucose urine present			
subjects affected / exposed	0 / 13 (0.00%)	1 / 21 (4.76%)	1 / 34 (2.94%)
occurrences (all)	0	1	1
Injury, poisoning and procedural complications			
Concussion			
subjects affected / exposed	1 / 13 (7.69%)	0 / 21 (0.00%)	1 / 34 (2.94%)
occurrences (all)	1	0	1
Joint dislocation			
subjects affected / exposed	0 / 13 (0.00%)	0 / 21 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Ligament sprain			
subjects affected / exposed	0 / 13 (0.00%)	0 / 21 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Limb injury			
subjects affected / exposed	1 / 13 (7.69%)	0 / 21 (0.00%)	1 / 34 (2.94%)
occurrences (all)	1	0	1
Road traffic accident			
subjects affected / exposed	1 / 13 (7.69%)	0 / 21 (0.00%)	1 / 34 (2.94%)
occurrences (all)	1	0	1
Sports injury			
subjects affected / exposed	0 / 13 (0.00%)	0 / 21 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Wound			
subjects affected / exposed	0 / 13 (0.00%)	1 / 21 (4.76%)	1 / 34 (2.94%)
occurrences (all)	0	1	1
Cardiac disorders			

Sinus arrest subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 21 (0.00%) 0	0 / 34 (0.00%) 0
Supraventricular extrasystoles subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 21 (0.00%) 0	0 / 34 (0.00%) 0
Nervous system disorders Headache subjects affected / exposed occurrences (all)	3 / 13 (23.08%) 4	1 / 21 (4.76%) 1	4 / 34 (11.76%) 5
Blood and lymphatic system disorders Increased tendency to bruise subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 21 (4.76%) 1	1 / 34 (2.94%) 1
Eye disorders Blepharospasm subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 21 (0.00%) 0	0 / 34 (0.00%) 0
Dry eye subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 21 (0.00%) 0	0 / 34 (0.00%) 0
Eye irritation subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 21 (0.00%) 0	0 / 34 (0.00%) 0
Eye pruritus subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 21 (0.00%) 0	0 / 34 (0.00%) 0
Gastrointestinal disorders Diarrhoea subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 21 (4.76%) 1	1 / 34 (2.94%) 1
Flatulence subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 21 (0.00%) 0	0 / 34 (0.00%) 0
Frequent bowel movements subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 21 (0.00%) 0	1 / 34 (2.94%) 1

Inguinal hernia subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 21 (0.00%) 0	0 / 34 (0.00%) 0
Lip dry subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 21 (0.00%) 0	0 / 34 (0.00%) 0
Nausea subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 21 (0.00%) 0	0 / 34 (0.00%) 0
Toothache subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	1 / 21 (4.76%) 1	2 / 34 (5.88%) 2
Skin and subcutaneous tissue disorders			
Acne subjects affected / exposed occurrences (all)	2 / 13 (15.38%) 2	0 / 21 (0.00%) 0	2 / 34 (5.88%) 2
Dermal cyst subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 21 (4.76%) 1	1 / 34 (2.94%) 1
Dermatitis subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 21 (0.00%) 0	0 / 34 (0.00%) 0
Diffuse alopecia subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 21 (0.00%) 0	0 / 34 (0.00%) 0
Dry skin subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	2 / 21 (9.52%) 2	2 / 34 (5.88%) 2
Erythema subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 21 (0.00%) 0	0 / 34 (0.00%) 0
Papule subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 21 (0.00%) 0	0 / 34 (0.00%) 0
Pityriasis rosea			

subjects affected / exposed	1 / 13 (7.69%)	0 / 21 (0.00%)	1 / 34 (2.94%)
occurrences (all)	1	0	1
Pruritus			
subjects affected / exposed	0 / 13 (0.00%)	1 / 21 (4.76%)	1 / 34 (2.94%)
occurrences (all)	0	1	1
Psoriasis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 21 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Rash maculo-papular			
subjects affected / exposed	0 / 13 (0.00%)	0 / 21 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Urticaria			
subjects affected / exposed	0 / 13 (0.00%)	0 / 21 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Micturition urgency			
subjects affected / exposed	0 / 13 (0.00%)	1 / 21 (4.76%)	1 / 34 (2.94%)
occurrences (all)	0	1	1
Pollakiuria			
subjects affected / exposed	0 / 13 (0.00%)	1 / 21 (4.76%)	1 / 34 (2.94%)
occurrences (all)	0	1	1
Proteinuria			
subjects affected / exposed	0 / 13 (0.00%)	0 / 21 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthritis			
subjects affected / exposed	1 / 13 (7.69%)	0 / 21 (0.00%)	1 / 34 (2.94%)
occurrences (all)	1	0	1
Back pain			
subjects affected / exposed	1 / 13 (7.69%)	0 / 21 (0.00%)	1 / 34 (2.94%)
occurrences (all)	1	0	1
Joint effusion			
subjects affected / exposed	0 / 13 (0.00%)	0 / 21 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Myalgia			

subjects affected / exposed	0 / 13 (0.00%)	0 / 21 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Neck pain			
subjects affected / exposed	1 / 13 (7.69%)	0 / 21 (0.00%)	1 / 34 (2.94%)
occurrences (all)	1	0	1
Pain in extremity			
subjects affected / exposed	0 / 13 (0.00%)	1 / 21 (4.76%)	1 / 34 (2.94%)
occurrences (all)	0	1	1
Infections and infestations			
Bacterial vaginosis			
subjects affected / exposed	1 / 13 (7.69%)	0 / 21 (0.00%)	1 / 34 (2.94%)
occurrences (all)	1	0	1
Bronchitis			
subjects affected / exposed	1 / 13 (7.69%)	0 / 21 (0.00%)	1 / 34 (2.94%)
occurrences (all)	1	0	1
Conjunctivitis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 21 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Cystitis			
subjects affected / exposed	1 / 13 (7.69%)	1 / 21 (4.76%)	2 / 34 (5.88%)
occurrences (all)	1	1	2
Fungal skin infection			
subjects affected / exposed	0 / 13 (0.00%)	0 / 21 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis			
subjects affected / exposed	1 / 13 (7.69%)	0 / 21 (0.00%)	1 / 34 (2.94%)
occurrences (all)	1	0	1
Gastroenteritis viral			
subjects affected / exposed	1 / 13 (7.69%)	0 / 21 (0.00%)	1 / 34 (2.94%)
occurrences (all)	1	0	1
Helicobacter gastritis			
subjects affected / exposed	0 / 13 (0.00%)	0 / 21 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Laryngitis			
subjects affected / exposed	0 / 13 (0.00%)	1 / 21 (4.76%)	1 / 34 (2.94%)
occurrences (all)	0	1	1

Nasopharyngitis subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	3 / 21 (14.29%) 3	4 / 34 (11.76%) 4
Oral herpes subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 21 (0.00%) 0	0 / 34 (0.00%) 0
Pharyngitis subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	1 / 21 (4.76%) 1	2 / 34 (5.88%) 2
Sinusitis subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 21 (0.00%) 0	0 / 34 (0.00%) 0
Tonsillitis subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 21 (0.00%) 0	0 / 34 (0.00%) 0
Tooth infection subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 21 (0.00%) 0	0 / 34 (0.00%) 0
Upper respiratory tract infection subjects affected / exposed occurrences (all)	2 / 13 (15.38%) 2	1 / 21 (4.76%) 1	3 / 34 (8.82%) 3
Urinary tract infection subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	1 / 21 (4.76%) 1	2 / 34 (5.88%) 2
Vulvovaginal mycotic infection subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	1 / 21 (4.76%) 1	1 / 34 (2.94%) 1
Metabolism and nutrition disorders Hypoglycaemia subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 21 (0.00%) 0	0 / 34 (0.00%) 0
Vitamin D deficiency subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0	0 / 21 (0.00%) 0	0 / 34 (0.00%) 0

Non-serious adverse events	Period 1 Placebo	Period 2 CJM112 high dose/CJM112 high dose	Period 2 Placebo/ CJM112 high dose
-----------------------------------	------------------	--	---------------------------------------

Total subjects affected by non-serious adverse events			
subjects affected / exposed	10 / 18 (55.56%)	10 / 17 (58.82%)	5 / 6 (83.33%)
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Fatigue			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Influenza like illness			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Injection site bruising			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Injection site reaction			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Non-cardiac chest pain			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Sensation of foreign body			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Seasonal allergy			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
Dysmenorrhoea			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			

Cough			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dyspnoea			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Nasal congestion			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Oropharyngeal pain			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Depression			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Blood creatinine increased			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood triglycerides increased			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Glucose urine present			

subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 17 (0.00%) 0	0 / 6 (0.00%) 0
Injury, poisoning and procedural complications			
Concussion			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Joint dislocation			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Ligament sprain			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Limb injury			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Road traffic accident			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Sports injury			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Wound			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Sinus arrest			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Supraventricular extrasystoles			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Nervous system disorders			
Headache			
subjects affected / exposed	1 / 18 (5.56%)	1 / 17 (5.88%)	0 / 6 (0.00%)
occurrences (all)	1	2	0
Blood and lymphatic system disorders			

Increased tendency to bruise subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 17 (0.00%) 0	0 / 6 (0.00%) 0
Eye disorders			
Blepharospasm subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 17 (0.00%) 0	1 / 6 (16.67%) 1
Dry eye subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 17 (0.00%) 0	0 / 6 (0.00%) 0
Eye irritation subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	1 / 17 (5.88%) 1	0 / 6 (0.00%) 0
Eye pruritus subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 17 (0.00%) 0	0 / 6 (0.00%) 0
Gastrointestinal disorders			
Diarrhoea subjects affected / exposed occurrences (all)	2 / 18 (11.11%) 2	1 / 17 (5.88%) 1	1 / 6 (16.67%) 1
Flatulence subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	0 / 17 (0.00%) 0	0 / 6 (0.00%) 0
Frequent bowel movements subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 17 (0.00%) 0	0 / 6 (0.00%) 0
Inguinal hernia subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	1 / 17 (5.88%) 1	0 / 6 (0.00%) 0
Lip dry subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 17 (0.00%) 0	0 / 6 (0.00%) 0
Nausea subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	1 / 17 (5.88%) 2	0 / 6 (0.00%) 0
Toothache			

subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 17 (0.00%) 0	0 / 6 (0.00%) 0
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dermal cyst			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dermatitis			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Diffuse alopecia			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Dry skin			
subjects affected / exposed	2 / 18 (11.11%)	0 / 17 (0.00%)	0 / 6 (0.00%)
occurrences (all)	2	0	0
Erythema			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Papule			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pityriasis rosea			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	3 / 18 (16.67%)	0 / 17 (0.00%)	1 / 6 (16.67%)
occurrences (all)	3	0	1
Psoriasis			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Rash maculo-papular			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0

Urticaria subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	0 / 17 (0.00%) 0	0 / 6 (0.00%) 0
Renal and urinary disorders			
Micturition urgency subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 17 (0.00%) 0	0 / 6 (0.00%) 0
Pollakiuria subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 17 (0.00%) 0	0 / 6 (0.00%) 0
Proteinuria subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 17 (0.00%) 0	0 / 6 (0.00%) 0
Musculoskeletal and connective tissue disorders			
Arthritis subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 17 (0.00%) 0	0 / 6 (0.00%) 0
Back pain subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	1 / 17 (5.88%) 1	0 / 6 (0.00%) 0
Joint effusion subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 17 (0.00%) 0	0 / 6 (0.00%) 0
Myalgia subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 17 (0.00%) 0	0 / 6 (0.00%) 0
Neck pain subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 17 (0.00%) 0	0 / 6 (0.00%) 0
Pain in extremity subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 17 (0.00%) 0	0 / 6 (0.00%) 0
Infections and infestations			
Bacterial vaginosis subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 17 (0.00%) 0	0 / 6 (0.00%) 0

Bronchitis			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Cystitis			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Fungal skin infection			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Gastroenteritis			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	1 / 6 (16.67%)
occurrences (all)	0	1	1
Gastroenteritis viral			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Helicobacter gastritis			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Laryngitis			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	1 / 18 (5.56%)	2 / 17 (11.76%)	0 / 6 (0.00%)
occurrences (all)	1	2	0
Oral herpes			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Pharyngitis			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Sinusitis			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Tonsillitis subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	1 / 17 (5.88%) 1	0 / 6 (0.00%) 0
Tooth infection subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 17 (0.00%) 0	1 / 6 (16.67%) 1
Upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	1 / 17 (5.88%) 1	1 / 6 (16.67%) 1
Urinary tract infection subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	2 / 17 (11.76%) 5	0 / 6 (0.00%) 0
Vulvovaginal mycotic infection subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 17 (0.00%) 0	0 / 6 (0.00%) 0
Metabolism and nutrition disorders Hypoglycaemia subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 17 (0.00%) 0	1 / 6 (16.67%) 1
Vitamin D deficiency subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	1 / 17 (5.88%) 1	0 / 6 (0.00%) 0

Non-serious adverse events	Period 2 CJM112 low dose/CJM112 low dose	Period 2 Placebo/CJM112 low dose	Period 2 Pooled CJM112 high dose
Total subjects affected by non-serious adverse events subjects affected / exposed	9 / 10 (90.00%)	5 / 8 (62.50%)	15 / 23 (65.22%)
General disorders and administration site conditions Asthenia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 8 (0.00%) 0	0 / 23 (0.00%) 0
Fatigue subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 8 (0.00%) 0	0 / 23 (0.00%) 0
Influenza like illness subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 8 (0.00%) 0	0 / 23 (0.00%) 0

Injection site bruising subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 8 (0.00%) 0	0 / 23 (0.00%) 0
Injection site reaction subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 8 (0.00%) 0	0 / 23 (0.00%) 0
Non-cardiac chest pain subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 8 (0.00%) 0	0 / 23 (0.00%) 0
Sensation of foreign body subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 8 (0.00%) 0	1 / 23 (4.35%) 1
Immune system disorders Hypersensitivity subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 8 (0.00%) 0	0 / 23 (0.00%) 0
Seasonal allergy subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 8 (0.00%) 0	0 / 23 (0.00%) 0
Reproductive system and breast disorders Dysmenorrhoea subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 8 (0.00%) 0	0 / 23 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 8 (0.00%) 0	0 / 23 (0.00%) 0
Dyspnoea subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 8 (0.00%) 0	0 / 23 (0.00%) 0
Nasal congestion subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 8 (0.00%) 0	1 / 23 (4.35%) 1
Oropharyngeal pain subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	1 / 8 (12.50%) 1	0 / 23 (0.00%) 0

Rhinorrhoea subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 8 (0.00%) 0	0 / 23 (0.00%) 0
Psychiatric disorders Depression subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 8 (0.00%) 0	0 / 23 (0.00%) 0
Investigations Alanine aminotransferase increased subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 8 (0.00%) 0	0 / 23 (0.00%) 0
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 8 (12.50%) 1	0 / 23 (0.00%) 0
Blood creatine phosphokinase increased subjects affected / exposed occurrences (all)	2 / 10 (20.00%) 2	1 / 8 (12.50%) 1	1 / 23 (4.35%) 1
Blood creatinine increased subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 8 (0.00%) 0	0 / 23 (0.00%) 0
Blood triglycerides increased subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 8 (0.00%) 0	0 / 23 (0.00%) 0
Glucose urine present subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 8 (0.00%) 0	0 / 23 (0.00%) 0
Injury, poisoning and procedural complications Concussion subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 8 (0.00%) 0	0 / 23 (0.00%) 0
Joint dislocation subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 8 (0.00%) 0	1 / 23 (4.35%) 1
Ligament sprain			

subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 8 (0.00%) 0	1 / 23 (4.35%) 1
Limb injury subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 8 (0.00%) 0	0 / 23 (0.00%) 0
Road traffic accident subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 8 (0.00%) 0	0 / 23 (0.00%) 0
Sports injury subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 8 (0.00%) 0	0 / 23 (0.00%) 0
Wound subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 8 (0.00%) 0	0 / 23 (0.00%) 0
Cardiac disorders Sinus arrest subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 8 (0.00%) 0	1 / 23 (4.35%) 1
Supraventricular extrasystoles subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 8 (0.00%) 0	1 / 23 (4.35%) 1
Nervous system disorders Headache subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 8 (0.00%) 0	1 / 23 (4.35%) 2
Blood and lymphatic system disorders Increased tendency to bruise subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 8 (0.00%) 0	0 / 23 (0.00%) 0
Eye disorders Blepharospasm subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 8 (0.00%) 0	1 / 23 (4.35%) 1
Dry eye subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 8 (12.50%) 1	0 / 23 (0.00%) 0
Eye irritation			

subjects affected / exposed	0 / 10 (0.00%)	0 / 8 (0.00%)	1 / 23 (4.35%)
occurrences (all)	0	0	1
Eye pruritus			
subjects affected / exposed	0 / 10 (0.00%)	1 / 8 (12.50%)	0 / 23 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	1 / 10 (10.00%)	0 / 8 (0.00%)	2 / 23 (8.70%)
occurrences (all)	1	0	2
Flatulence			
subjects affected / exposed	0 / 10 (0.00%)	0 / 8 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Frequent bowel movements			
subjects affected / exposed	0 / 10 (0.00%)	0 / 8 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Inguinal hernia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 8 (0.00%)	1 / 23 (4.35%)
occurrences (all)	0	0	1
Lip dry			
subjects affected / exposed	1 / 10 (10.00%)	0 / 8 (0.00%)	0 / 23 (0.00%)
occurrences (all)	1	0	0
Nausea			
subjects affected / exposed	0 / 10 (0.00%)	0 / 8 (0.00%)	1 / 23 (4.35%)
occurrences (all)	0	0	2
Toothache			
subjects affected / exposed	0 / 10 (0.00%)	0 / 8 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	0 / 10 (0.00%)	0 / 8 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Dermal cyst			
subjects affected / exposed	0 / 10 (0.00%)	0 / 8 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Dermatitis			

subjects affected / exposed	0 / 10 (0.00%)	0 / 8 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Diffuse alopecia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 8 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	1 / 10 (10.00%)	0 / 8 (0.00%)	0 / 23 (0.00%)
occurrences (all)	1	0	0
Erythema			
subjects affected / exposed	0 / 10 (0.00%)	0 / 8 (0.00%)	1 / 23 (4.35%)
occurrences (all)	0	0	1
Papule			
subjects affected / exposed	0 / 10 (0.00%)	1 / 8 (12.50%)	0 / 23 (0.00%)
occurrences (all)	0	1	0
Pityriasis rosea			
subjects affected / exposed	0 / 10 (0.00%)	0 / 8 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	0 / 10 (0.00%)	0 / 8 (0.00%)	1 / 23 (4.35%)
occurrences (all)	0	0	1
Psoriasis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 8 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Rash maculo-papular			
subjects affected / exposed	0 / 10 (0.00%)	0 / 8 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Urticaria			
subjects affected / exposed	0 / 10 (0.00%)	0 / 8 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Micturition urgency			
subjects affected / exposed	1 / 10 (10.00%)	0 / 8 (0.00%)	0 / 23 (0.00%)
occurrences (all)	1	0	0
Pollakiuria			
subjects affected / exposed	1 / 10 (10.00%)	0 / 8 (0.00%)	0 / 23 (0.00%)
occurrences (all)	1	0	0

Proteinuria subjects affected / exposed occurrences (all)	2 / 10 (20.00%) 3	1 / 8 (12.50%) 1	0 / 23 (0.00%) 0
Musculoskeletal and connective tissue disorders			
Arthritis subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 0	0 / 8 (0.00%) 0	0 / 23 (0.00%) 0
Back pain subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 8 (0.00%) 0	1 / 23 (4.35%) 1
Joint effusion subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 8 (0.00%) 0	0 / 23 (0.00%) 0
Myalgia subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	1 / 8 (12.50%) 1	0 / 23 (0.00%) 0
Neck pain subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 8 (0.00%) 0	0 / 23 (0.00%) 0
Pain in extremity subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 8 (0.00%) 0	0 / 23 (0.00%) 0
Infections and infestations			
Bacterial vaginosis subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 8 (0.00%) 0	0 / 23 (0.00%) 0
Bronchitis subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 8 (0.00%) 0	0 / 23 (0.00%) 0
Conjunctivitis subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 8 (12.50%) 1	0 / 23 (0.00%) 0
Cystitis subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 8 (0.00%) 0	0 / 23 (0.00%) 0
Fungal skin infection			

subjects affected / exposed	0 / 10 (0.00%)	0 / 8 (0.00%)	1 / 23 (4.35%)
occurrences (all)	0	0	1
Gastroenteritis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 8 (0.00%)	2 / 23 (8.70%)
occurrences (all)	0	0	2
Gastroenteritis viral			
subjects affected / exposed	0 / 10 (0.00%)	0 / 8 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Helicobacter gastritis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 8 (0.00%)	1 / 23 (4.35%)
occurrences (all)	0	0	1
Laryngitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 8 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	1 / 10 (10.00%)	2 / 8 (25.00%)	2 / 23 (8.70%)
occurrences (all)	1	3	2
Oral herpes			
subjects affected / exposed	0 / 10 (0.00%)	0 / 8 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Pharyngitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 8 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Sinusitis			
subjects affected / exposed	0 / 10 (0.00%)	1 / 8 (12.50%)	0 / 23 (0.00%)
occurrences (all)	0	1	0
Tonsillitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 8 (0.00%)	1 / 23 (4.35%)
occurrences (all)	0	0	1
Tooth infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 8 (0.00%)	1 / 23 (4.35%)
occurrences (all)	0	0	1
Upper respiratory tract infection			
subjects affected / exposed	2 / 10 (20.00%)	0 / 8 (0.00%)	2 / 23 (8.70%)
occurrences (all)	3	0	2
Urinary tract infection			

subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 8 (12.50%) 1	2 / 23 (8.70%) 5
Vulvovaginal mycotic infection subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 8 (0.00%) 0	0 / 23 (0.00%) 0
Metabolism and nutrition disorders			
Hypoglycaemia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 8 (0.00%) 0	1 / 23 (4.35%) 1
Vitamin D deficiency subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 8 (0.00%) 0	1 / 23 (4.35%) 1

Non-serious adverse events	Period 2 Pooled CJM112 low dose		
Total subjects affected by non-serious adverse events subjects affected / exposed	14 / 18 (77.78%)		
General disorders and administration site conditions			
Asthenia subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Fatigue subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Influenza like illness subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Injection site bruising subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Injection site reaction subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Non-cardiac chest pain subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Sensation of foreign body			

subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Immune system disorders Hypersensitivity subjects affected / exposed occurrences (all) Seasonal allergy subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0 1 / 18 (5.56%) 1		
Reproductive system and breast disorders Dysmenorrhoea subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all) Dyspnoea subjects affected / exposed occurrences (all) Nasal congestion subjects affected / exposed occurrences (all) Oropharyngeal pain subjects affected / exposed occurrences (all) Rhinorrhoea subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0 0 / 18 (0.00%) 0 0 / 18 (0.00%) 0 2 / 18 (11.11%) 2 0 / 18 (0.00%) 0		
Psychiatric disorders Depression subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0		
Investigations Alanine aminotransferase increased			

subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Blood creatine phosphokinase increased			
subjects affected / exposed	3 / 18 (16.67%)		
occurrences (all)	3		
Blood creatinine increased			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Blood triglycerides increased			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Glucose urine present			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Injury, poisoning and procedural complications			
Concussion			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Joint dislocation			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Ligament sprain			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Limb injury			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Road traffic accident			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Sports injury			

subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Wound			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Cardiac disorders			
Sinus arrest			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Supraventricular extrasystoles			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Nervous system disorders			
Headache			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Blood and lymphatic system disorders			
Increased tendency to bruise			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Eye disorders			
Blepharospasm			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Dry eye			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Eye irritation			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Eye pruritus			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		

Flatulence			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Frequent bowel movements			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Inguinal hernia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Lip dry			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Nausea			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Toothache			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Dermal cyst			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Dermatitis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Diffuse alopecia			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Dry skin			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Erythema			

subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Papule			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Pityriasis rosea			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Pruritus			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Psoriasis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Rash maculo-papular			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Urticaria			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Renal and urinary disorders			
Micturition urgency			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Pollakiuria			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Proteinuria			
subjects affected / exposed	3 / 18 (16.67%)		
occurrences (all)	4		
Musculoskeletal and connective tissue disorders			
Arthritis			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	0		
Back pain			

subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Joint effusion			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Myalgia			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	2		
Neck pain			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Pain in extremity			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Infections and infestations			
Bacterial vaginosis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Bronchitis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Conjunctivitis			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Cystitis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Fungal skin infection			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Gastroenteritis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Gastroenteritis viral			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		

Helicobacter gastritis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Laryngitis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Nasopharyngitis			
subjects affected / exposed	3 / 18 (16.67%)		
occurrences (all)	4		
Oral herpes			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Pharyngitis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Sinusitis			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Tonsillitis			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Tooth infection			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Upper respiratory tract infection			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	3		
Urinary tract infection			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Vulvovaginal mycotic infection			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Metabolism and nutrition disorders			
Hypoglycaemia			

subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		
Vitamin D deficiency			
subjects affected / exposed	0 / 18 (0.00%)		
occurrences (all)	0		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
14 November 2016	The study population had been redefined such that adolescent subjects were excluded from the study, as per the guidance from the ethics committees. As a result, subjects aged 18-45 years were only eligible. The amendment was implemented prior to FPFV.
14 December 2016	Changes were made to the inclusion criteria to include only adults who have failed other systemic therapies for inflammatory acne. Changes were also made to sample size that was reduced from 90 to 75 subjects. A study design change was implemented that offers the subjects at week 12 an option to continue in an extension period. The amendment was implemented prior to FPFV.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported